德孚在中国

9 0 5 7 8

论文已发表

提 交 论 文


注册即可获取德孚的最新动态

注 册



IF 收录期刊





更多详情 >>





已发表论文

作为实体瘤的一种多靶点酪氨酸激酶抑制剂 (TKI)，舒尼替尼的临床反应：一项临床试验评估

 

Authors Kim S, Ding W, Zhang L, Tian W, Chen S

Published Date May 2014 Volume 2014:7 Pages 719—728

DOI http://dx.doi.org/10.2147/OTT.S61388

Received 27 January 2014, Accepted 11 March 2014, Published 12 May 2014

Abstract: Angiogenesis is an integral process in carcinogenesis, and molecular inhibitors of angiogenic factors are currently being tested as treatments for cancer. Sunitinib is an oral multitargeted tyrosine-kinase inhibitor that blocks activation through the stem cell-factor receptor (Kit) and platelet-derived growth-factor receptor. Sunitinib has shown potent antitumor activity against several solid tumors, including renal cell carcinoma, gastrointestinal stromal tumors, and neuroendocrine tumors in several Phase II/III trials. Recently, sunitinib has been used to treat other solid cancers, such as lung cancer, pancreatic cancer, chondrosarcoma, esophageal cancer, bladder cancer, glioma, and aggressive fibromatosis, and also showed potential efficacy in progression-free survival and overall survival. In this review, we examine the efficacy of sunitinib as a molecular-targeted therapy in patients with different types of solid cancers.
Keywords: anti-angiogenic therapy, molecular-targeted therapy, tumor, antitumor activity





Download Article[PDF]